Clinical trials: Clostridioides Difficile Infection
Nosocomial Infections, Bloodstream Infection
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.
- Conditions
- Nosocomial Infections, Bloodstream Infection, Invasive Aspergillosis
- Trial name
- Oncoped2006 (NCT00843804)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bonn
Inflammatory Bowel Diseases, Clostridium Infections
Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
In recent years, the incidence of Inflammatory Bowel Disease (IBD) has been increasing in China, which poses great challenges and burdens to the medical community due to its unknown etiology, recurrence and incurability.
- Trial name
- NCT04179201
- Where
- 6 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Clostridioides Difficile Infection
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
- Trial name
- Ri-CoDIFy 3 (NCT04802837)
- Testing
- Ridinilazole, Vancomycin
- Where
- 18 sites in United States
- Volunteers
- 2 people
- Sponsor
- Summit Therapeutics
Clostridium Difficile Infection
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01914731
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clostridioides Difficile Infection
Study of Clostridioides Difficile in Infants
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually.
- Trial name
- NCT06788769
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Westlake University
Clostridium Difficile Infection
COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary…
- Trial name
- COMBACTE-CDI (NCT03503474)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- University of Leeds
C. Difficile Infection
Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy
The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C.
- Trial name
- c diff (NCT01472978)
- Testing
- metronidazole
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Fecal Microbiota Transplantation, Clostridium Difficile Infection
Fecal Microbiota Transplant National Registry
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
- Conditions
- Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
- Trial name
- FMT (NCT03325855)
- Testing
- None - Observational
- Where
- 53 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- American Gastroenterological Association
Recurrent Clostridium Difficile Infection, Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call.
- Trial name
- NCT03786900
- Testing
- Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727
- Sponsor
- Herbert DuPont, MD
Clostridium Difficile Infection, Diet Modification
Specific Carbohydrate Diet for Clostridium Difficile
The investigators are doing this research study to answer questions about a nutritional therapy called the Specific Carbohydrate Diet (SCD) for children with active Clostridium Difficile Infection.
- Trial name
- SCD_cDiff (NCT03925636)
- Testing
- Specific Carbohydrate Diet
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- David Suskind
Clostridium Difficile Infection
Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection
Investigators designed an open, two-arm study to compare fecal microbiota transplant by oral capsules (FMT-c ) versus FMT-c enriched with Lactobacillus for treatment of C. difficile recurrent infection
- Trial name
- NCT03804736
- Testing
- FMT-c, FMT-c Lactobacillus
- Volunteers
- 21 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Clostridium Difficile, Clostridium Difficile Infection
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
To assess the association between Clostridium difficile (CD) toxins' serum levels and the grade of Clostridium difficile infection (CDI) severity/failure to CDI treatment and rate of recurrence.
- Trial name
- NCT03586206
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Roma Tre University
Multidrug Resistant Organisms, Healthcare Associated Infections
Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)
Enhanced terminal room disinfection is a novel, promising, but still unproven strategy for the prevention of healthcare-associated infections (HAIs) due to selected multidrug-resistant (MDR) bacterial pathogens.
- Trial name
- NCT01579370
- Testing
- Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light
- Where
- 9 sites in United States
- Volunteers
- 21,395 people
- Sponsor
- Duke University
Recurrent Clostridium Difficile Infection
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.
- Trial name
- NCT03834038
- Testing
- Lyophilized Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 158 people
- Sponsor
- Vancouver Island Health Authority
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Clostridium Difficile Infection
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile…
- Trial name
- MODIFY III (NCT03182907)
- Testing
- Bezlotoxumab, Antibacterial drug treatment (ABD)
- Where
- 75 sites in United States, Argentina and 15 more
- Volunteers
- 148 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Difficile Infection
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
Acquiring diarrhoea in hospital is a serious problem and most frequently occurs when susceptible patients receive antibiotics as part of their (often life-saving) care.
- Trial name
- NCT02086916
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Barts & The London NHS Trust
Clostridium Difficile
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon.
- Trial name
- FMT (NCT02134392)
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonathan Gisser
Clostridium Difficile-associated Diarrhea (CDAD)
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
The purpose of this study was to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules in pediatric participants with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- SUNSHINE (NCT02218372)
- Testing
- Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid
- Where
- 44 sites in United States, Belgium and 8 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.